Other studies evaluate the inhibition of S100A4 protein function with S100A4-specific antibodies, or by blocking its binding to RAGE with antagonistic peptides, shown for glioma and pancreatic cancer [13, 29, 30]. The gene discussed is S100A4; the disease is central nervous system cancer.